Trial Profile
A Randomized Controlled, Double-Masked, Crossover Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of 1.0 Mg Luminate (Alg-1001) As A Treatment For Non-Exudative Macular Degeneration
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Aug 2022
Price :
$35
*
At a glance
- Drugs Risuteganib (Primary)
- Indications Dry age-related macular degeneration
- Focus Proof of concept; Therapeutic Use
- Sponsors Allegro Ophthalmics
- 01 Aug 2022 Results published in the Ophthalmic Surgery, Lasers & Imaging Retina
- 03 Aug 2021 Results published in the Allegro Ophthalmics Media Release.
- 03 Aug 2021 According to an Allegro Ophthalmics media release, results from the study are published in Ophthalmic Surgery, Lasers, and Imaging (OSLI) Retina. David S. Boyer is the lead author of the publication.